Advertisement
Allogeneic CAR T-Cell Therapy: A Promising Frontier in Cancer Treatment
Author: Dr. Evelyn Reed, PhD, MD; Professor of Hematology and Oncology, Harvard Medical School; Principal Investigator, Center for Cellular Immunotherapies.
Keywords: allogeneic CAR T-cell therapy, CAR T-cell therapy, adoptive cell therapy, cancer immunotherapy, off-the-shelf therapy, allogeneic cells, chimeric antigen receptor, graft-versus-tumor effect, immune rejection, manufacturing challenges.
Abstract: Allogeneic CAR T-cell therapy represents a significant advancement in cancer treatment, offering the potential for a widely accessible, off-the-shelf therapeutic approach. While autologous CAR T-cell therapy has shown remarkable success, its lengthy manufacturing process and high cost limit its accessibility. Allogeneic CAR T-cell therapy, using donor-derived T cells, aims to overcome these limitations. However, significant challenges remain, primarily concerning immune rejection and the potential for graft-versus-host disease. This article explores the opportunities and challenges associated with allogeneic CAR T-cell therapy, examining current research and future directions in this rapidly evolving field.
1. Introduction: Reimagining CAR T-Cell Therapy with Allogeneic Approaches
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of certain hematological malignancies. Autologous CAR T-cell therapy, where a patient's own T cells are genetically modified and reinfused, has demonstrated impressive efficacy in some instances. However, this approach is hampered by its high cost, lengthy manufacturing time (often several weeks), and the inability to treat patients whose cells are unsuitable for modification.
Allogeneic CAR T-cell therapy offers a potential solution to these limitations. By using healthy donor T cells, this approach offers the possibility of an "off-the-shelf" therapy, readily available for immediate use. This would significantly reduce manufacturing time and cost, making CAR T-cell therapy accessible to a much wider patient population.
2. The Mechanics of Allogeneic CAR T-Cell Therapy
The process begins with collecting T cells from a healthy donor. These cells are then genetically engineered to express a CAR targeting a specific antigen, typically found on the surface of cancer cells. Rigorous quality control ensures the safety and efficacy of the modified cells. The allogeneic CAR T cells are then infused into the patient, where they proliferate and eliminate cancer cells expressing the target antigen.
A key difference from autologous therapy is the introduction of donor cells into a recipient, raising the potential for immune rejection and graft-versus-host disease (GvHD). This is a major challenge that requires innovative strategies to overcome.
3. Overcoming the Challenges: Immune Rejection and GvHD
Immune rejection, where the recipient's immune system attacks the donor T cells, is a significant hurdle in allogeneic CAR T-cell therapy. Strategies to mitigate this include:
Immune suppression: Using immunosuppressive drugs to dampen the recipient's immune response.
Genetic engineering: Modifying donor T cells to reduce their immunogenicity. This can involve removing or modifying genes associated with immune recognition.
HLA matching: Selecting donors with HLA (human leukocyte antigen) types that are closely matched to the recipient, minimizing the chance of rejection.
Graft-versus-host disease (GvHD) is another critical concern. This occurs when the donor T cells attack the recipient's healthy tissues. Strategies to minimize GvHD include:
Careful donor selection: Choosing donors with minimal risk of GvHD.
T cell engineering: Modifying T cells to reduce their capacity to cause GvHD. This can involve removing or modifying specific T cell subsets.
Post-transplant management: Careful monitoring and management of GvHD using immunosuppressive medications.
4. Opportunities and Potential of Allogeneic CAR T-Cell Therapy
Despite the challenges, allogeneic CAR T-cell therapy holds immense promise. Its potential advantages include:
Reduced cost and manufacturing time: The "off-the-shelf" nature of allogeneic therapy significantly reduces manufacturing costs and time, making it more accessible to patients.
Potential for broader application: Allogeneic CAR T cells can potentially be used to treat a wider range of cancers and patient populations.
Synergistic combinations: Allogeneic CAR T-cell therapy can be combined with other cancer therapies, such as chemotherapy or radiation, to enhance efficacy.
Graft-versus-tumor effect: Donor T cells can exert a graft-versus-tumor (GvT) effect, targeting residual cancer cells that might not be eradicated by the CAR T cells alone. This can lead to improved long-term outcomes.
5. Current Research and Future Directions
Significant research efforts are underway to refine allogeneic CAR T-cell therapy and overcome its challenges. These include:
Development of novel CAR designs: Improving CAR specificity and efficacy to minimize off-target effects.
Advanced T cell engineering: Further refining methods to reduce immunogenicity and GvHD risk.
Improved manufacturing processes: Developing more efficient and scalable manufacturing methods to meet the growing demand.
Clinical trials: Ongoing clinical trials are evaluating the safety and efficacy of allogeneic CAR T-cell therapy in various cancer types.
6. Conclusion
Allogeneic CAR T-cell therapy represents a transformative approach to cancer treatment. While challenges related to immune rejection and GvHD remain, ongoing research and innovative strategies are paving the way for its broader clinical application. The potential to deliver a cost-effective, readily available therapy with the potential for improved outcomes holds immense promise for patients battling a wide range of cancers. As research continues to refine this technology, allogeneic CAR T-cell therapy is poised to play an increasingly significant role in the fight against cancer.
FAQs
1. What is the difference between autologous and allogeneic CAR T-cell therapy? Autologous uses a patient's own cells, while allogeneic uses donor cells.
2. What are the risks of allogeneic CAR T-cell therapy? The primary risks are immune rejection and graft-versus-host disease (GvHD).
3. How long does it take to manufacture allogeneic CAR T cells? Significantly less time than autologous, potentially days to weeks, rather than weeks.
4. Is allogeneic CAR T-cell therapy suitable for all cancer types? Currently, research is focused on specific hematological malignancies, with expansion to solid tumors being investigated.
5. What is the cost of allogeneic CAR T-cell therapy compared to autologous? Allogeneic is expected to be significantly less expensive.
6. What are the long-term effects of allogeneic CAR T-cell therapy? Long-term studies are ongoing to determine potential long-term effects.
7. How is GvHD treated? GvHD is managed with immunosuppressive medications and supportive care.
8. What are the success rates of allogeneic CAR T-cell therapy? Success rates vary depending on the cancer type and the specific treatment protocol. Clinical trials are ongoing to better determine efficacy.
9. Where can I find more information on clinical trials for allogeneic CAR T-cell therapy? ClinicalTrials.gov is a good resource for locating clinical trials.
Related Articles:
1. "Overcoming Immune Rejection in Allogeneic CAR T-Cell Therapy: A Review of Current Strategies": This article reviews current approaches to reducing immune rejection in allogeneic CAR T-cell therapy, including immune suppression and genetic engineering techniques.
2. "Manufacturing Challenges and Solutions in Allogeneic CAR T-Cell Therapy": This article explores the manufacturing challenges associated with allogeneic CAR T-cell therapy and discusses potential solutions for improving efficiency and scalability.
3. "The Graft-versus-Tumor Effect in Allogeneic CAR T-Cell Therapy: Mechanisms and Clinical Implications": This article examines the GvT effect and its role in improving treatment outcomes.
4. "Allogeneic CAR T-Cell Therapy for Multiple Myeloma: A Promising New Frontier": This article focuses on the application of allogeneic CAR T-cell therapy in multiple myeloma.
5. "Comparison of Autologous and Allogeneic CAR T-Cell Therapy: A Head-to-Head Analysis": This article compares the efficacy, safety, and cost-effectiveness of autologous and allogeneic CAR T-cell therapy.
6. "Genetic Engineering Strategies to Reduce Immunogenicity in Allogeneic CAR T Cells": This article details various genetic engineering strategies aimed at reducing immune rejection.
7. "Clinical Trials Evaluating Allogeneic CAR T-Cell Therapy for Acute Lymphoblastic Leukemia": This article summarizes the results of clinical trials investigating allogeneic CAR T-cell therapy for acute lymphoblastic leukemia.
8. "Long-Term Follow-Up of Patients Treated with Allogeneic CAR T-Cell Therapy": This article presents long-term follow-up data on patients who have received allogeneic CAR T-cell therapy.
9. "The Role of Immunosuppression in Managing Graft-versus-Host Disease Following Allogeneic CAR T-Cell Therapy": This article discusses the role of immunosuppression in managing GvHD following allogeneic CAR T-cell therapy.
Publisher: The Journal of Immunotherapy, a peer-reviewed journal published by Elsevier, a leading publisher of scientific literature with a strong reputation in the biomedical field.
Editor: Dr. Anthony Carter, MD, PhD; Professor of Immunology, Stanford University; expert in cellular immunotherapy and transplantation immunology.
| allogeneic car t therapy: The EBMT/EHA CAR-T Cell Handbook Nicolaus Kröger, John Gribben, Christian Chabannon, Ibrahim Yakoub-Agha, Hermann Einsele, 2022-02-07 This first open access European CAR-T Handbook, co-promoted by the European Society for Blood and Marrow Transplantation (EBMT) and the European Hematology Association (EHA), covers several aspects of CAR-T cell treatments, including the underlying biology, indications, management of side-effects, access and manufacturing issues. This book, written by leading experts in the field to enhance readers’ knowledge and practice skills, provides an unparalleled overview of the CAR-T cell technology and its application in clinical care, to enhance readers’ knowledge and practice skills. |
| allogeneic car t therapy: Haploidentical Transplantation Stefan O. Ciurea, Rupert Handgretinger, 2018-05-03 In this book, world-renowned experts in the field express well-reasoned opinions on a range of issues and controversies relating to haploidentical transplantation with the aim of providing practicing hematologists with clinically relevant and readily applicable information. Among the areas covered are graft manipulation and methods to control T-cell alloreactivity, the nature of the ideal graft and donor, haploidentical transplantation in pediatric and adult patients with malignant and nonmalignant diseases, immunologic reconstitution following transplantation, complications, and the prevention and treatment of relapse post transplantation. Attention is drawn to the implications of high-impact clinical trials whenever such trials are available. The readily intelligible text is complemented by numerous helpful tables, algorithms, and figures. The book will provide practical support for hematologists and transplant physicians as they attempt to provide optimal care in this exciting but increasingly complex medical specialty. |
| allogeneic car t therapy: Chimeric Antigen Receptor T-Cell Therapies for Cancer E-Book Daniel W. Lee, Nirali N. Shah, 2019-11-30 From patient referral to post-therapy management, Chimeric Antigen Receptor (CAR) T-Cell Therapies for Cancer: A Practical Guide presents a comprehensive view of CAR modified T-cells in a concise and practical format. Providing authoritative guidance on the implementation and management of CAR T-cell therapy from Drs. Daniel W. Lee and Nirali N. Shah, this clinical resource keeps you up to date on the latest developments in this rapidly evolving area. - Covers all clinical aspects, including patient referral, toxicities management, comorbidities, bridging therapy, post-CAR monitoring, and multidisciplinary approaches to supportive care. - Includes key topics on associated toxicities such as predictive biomarkers, infections, and multidisciplinary approaches to supportive care. - Presents current knowledge on FDA approved CAR T-cell products as well as developments on the horizon. - Editors and authors represent leading investigators in academia and worldwide pioneers of CAR therapy. |
| allogeneic car t therapy: Developing Costimulatory Molecules for Immunotherapy of Diseases Manzoor Ahmad Mir, 2015-05-25 Developing Costimulatory Molecules for Immunotherapy of Diseases highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy using either humanized antibodies against CD80, CD86, and other costimulatory molecules or CD28 fusinogenic proteins in the treatment of diseases, including allergies, asthma, rheumatoid arthritis, multiple sclerosis, lupus nephritis, severe psoriasis, vulgaris tuberculosis, thopoid, transplantation therapeutic, cancer, and inflammation. The text aims to provide the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families, with the hope that targeting these families will yield new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases. - Highlights the novel concept of reverse costimulation and how it can be effectively exploited to develop immunotherapy - Provides the latest information on the complex roles and interactions within the CD28 and B7 costimulatory families - Targets new therapies for the treatment of inflammation, autoimmunity, transplantation, cancer, and other infectious diseases |
| allogeneic car t therapy: Cancer Immunology and Immunotherapy Mansoor M. Amiji, Lara Scheherazade Milane, 2021-08-18 Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. - Comprehensive treaty covering all aspects of immuno-oncology (IO) - Novel strategies for delivery of IO therapeutics and vaccines - Forecasting on the future of nanotechnology and drug delivery for IO |
| allogeneic car t therapy: Translational Regenerative Medicine Anthony Atala, Julie Allickson, 2014-12-01 Translational Regenerative Medicine is a reference book that outlines the life cycle for effective implementation of discoveries in the dynamic field of regenerative medicine. By addressing science, technology, development, regulatory, manufacturing, intellectual property, investment, financial, and clinical aspects of the field, this work takes a holistic look at the translation of science and disseminates knowledge for practical use of regenerative medicine tools, therapeutics, and diagnostics. Incorporating contributions from leaders in the fields of translational science across academia, industry, and government, this book establishes a more fluid transition for rapid translation of research to enhance human health and well-being. - Provides formulaic coverage of the landscape, process development, manufacturing, challenges, evaluation, and regulatory aspects of the most promising regenerative medicine clinical applications - Covers clinical aspects of regenerative medicine related to skin, cartilage, tendons, ligaments, joints, bone, fat, muscle, vascular system, hematopoietic /immune system, peripheral nerve, central nervous system, endocrine system, ophthalmic system, auditory system, oral system, respiratory system, cardiac system, renal system, hepatic system, gastrointestinal system, genitourinary system - Identifies effective, proven tools and metrics to identify and pursue clinical and commercial regenerative medicine |
| allogeneic car t therapy: Exploring Novel Clinical Trial Designs for Gene-Based Therapies National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Forum on Regenerative Medicine, 2020-08-27 Recognizing the potential design complexities and ethical issues associated with clinical trials for gene therapies, the Forum on Regenerative Medicine of the National Academies of Sciences, Engineering, and Medicine held a 1-day workshop in Washington, DC, on November 13, 2019. Speakers at the workshop discussed patient recruitment and selection for gene-based clinical trials, explored how the safety of new therapies is assessed, reviewed the challenges involving dose escalation, and spoke about ethical issues such as informed consent and the role of clinicians in recommending trials as options to their patients. The workshop also included discussions of topics related to gene therapies in the context of other available and potentially curative treatments, such as bone marrow transplantation for hemoglobinopathies. This publication summarizes the presentation and discussion of the workshop. |
| allogeneic car t therapy: Stem Cells – From Hype to Real Hope Khawaja Husnain Haider, Salim Aziz, MD, 2018-12-17 This book is a compilation of the bench experience of leading experts from various research labs involved in the cutting edge area of research. The authors describe the use of stem cells both as part of the combinatorial therapeutic intervention approach and as tools (disease model) during drug development, highlighting the shift from a conventional symptomatic treatment strategy to addressing the root cause of the disease process. The book is a continuum of the previously published book entitled Stem Cells: from Drug to Drug Discovery which was published in 2017. |
| allogeneic car t therapy: EBMT HANDBOOK , 2025 |
| allogeneic car t therapy: Blood and Marrow Transplant Handbook Richard T. Maziarz, Susan Schubach Slater, 2015-04-20 This updated and expanded edition developed by the Blood and Marrow Stem Cell Transplant team at Oregon Health & Science University Knight Cancer Institute features the latest medical management guidelines and standards of care for hematopoietic stem cell transplant patients. Spanning the timeline from the initial consultation throughout the transplant process, this handbook includes indications for transplantation and donor selection, treatment guidelines for addressing complications during and after transplant, and recommendations for long-term follow up care. Concise, comprehensive, and easy-to-use, Blood and Marrow Transplant Handbook, 2nd Edition presents a multidisciplinary approach to information for physicians and advanced practice medical providers who care for transplant patients, and also residents, fellows, and other trainees. |
| allogeneic car t therapy: Basics of Chimeric Antigen Receptor (CAR) Immunotherapy Mumtaz Y. Balkhi, 2019-07-31 Basics of Chimeric Antigen Receptor (CAR) Immunotherapy presents the latest on how T cell adoptive immunotherapy has progressed in its ultimate goal of curing metastatic malignant cancers. Recent clinical data obtained with checkpoint receptor blockade inhibitors and chimeric antigen receptor (CAR) therapy has been especially promising, thus generating renewed hope that we may be on the verge of finally curing cancer. Over the years, huge progress has been made in controlling several stage IV metastasized cancers through the clinical application of checkpoint receptor inhibitory drugs and CAR-Therapy that has seen unprecedented interest in the immunotherapy field. - Presents the first book to provide a basic understanding of chimeric antigen receptor (CARs) design, production and clinical application protocols - Provides unique authority as the editor has worked directly with CARs - Discusses the challenges encountered in actual clinical trials and how these challenges can be overcome - Includes a full chapter on various challenges researchers should expect to encounter in the CAR-therapy field |
| allogeneic car t therapy: Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy Mahmoud Aljurf, John A. Snowden, Patrick Hayden, Kim H. Orchard, Eoin McGrath, 2021-02-19 This open access book provides a concise yet comprehensive overview on how to build a quality management program for hematopoietic stem cell transplantation (HSCT) and cellular therapy. The text reviews all the essential steps and elements necessary for establishing a quality management program and achieving accreditation in HSCT and cellular therapy. Specific areas of focus include document development and implementation, audits and validation, performance measurement, writing a quality management plan, the accreditation process, data management, and maintaining a quality management program. Written by experts in the field, Quality Management and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy: A Practical Guide is a valuable resource for physicians, healthcare professionals, and laboratory staff involved in the creation and maintenance of a state-of-the-art HSCT and cellular therapy program. |
| allogeneic car t therapy: Drug Resistance in Leukemia & Gert-Jan L. Kaspers, 1993-01-01 The last ten years have seen the publication of a vast amount of data regarding cellular resistance to drugs in cancer cells. Recent studies have demonstrated that drug resistance assays appear to be predictive of clinical response and suggest that clinicians should now be considering the potential applications of these assays in the treatment of patients with hematological neoplasms. This collection of papers from the International Symposium on the Clinical Value of Drug Resistance Assays in Leukemia and Lymphoma, Amsterdam, 1992, provides a state-of-the-art discussion on drug resistance assays and their role in the design and individualization of treatment protocols. |
| allogeneic car t therapy: Childhood Acute Lymphoblastic Leukemia Ajay Vora, 2017-04-21 This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia. |
| allogeneic car t therapy: The European Blood and Marrow Transplantation Textbook for Nurses Michelle Kenyon, Aleksandra Babic, 2018-03-14 This book is open access under a CC BY 4.0 license. This textbook, endorsed by the European Society for Blood and Marrow Transplantation (EBMT), provides adult and paediatric nurses with a full and informative guide covering all aspects of transplant nursing, from basic principles to advanced concepts. It takes the reader on a journey through the history of transplant nursing, including essential and progressive elements to help nurses improve their knowledge and benefit the patient experience, as well as a comprehensive introduction to research and auditing methods. This new volume specifically intended for nurses, complements the ESH-EBMT reference title, a popular educational resource originally developed in 2003 for physicians to accompany an annual training course also serving as an educational tool in its own right. This title is designed to develop the knowledge of nurses in transplantation. It is the first book of its kind specifically targeted at nurses in this specialist field and acknowledges the valuable contribution that nursing makes in this area. This volume presents information that is essential for the education of nurses new to transplantation, while also offering a valuable resource for more experienced nurses who wish to update their knowledge. |
| allogeneic car t therapy: Guide to Immunotherapy Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2018-10 |
| allogeneic car t therapy: Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases Richard K. Burt, Dominique Farge, Milton A. Ruiz, Riccardo Saccardi, John A. Snowden, 2021-11-17 This book summarizes the global progress in medical and scientific research toward converting traditionally chronic autoimmune diseases into a drug-free reversible illness using hematopoietic stem cell transplantation (HSCT) and other cellular therapies such as T regulatory cells (Treg), mesenchymal stromal/stem cells, and chimeric antigen receptor T (CAR T) cells in order to reintroduce sustained immune tolerance. This title provides information on different types of stem cells and immune cells; post-transplant immune regeneration; cellular regulatory requirements; ethical and economic considerations; and the advantages and disadvantages of HSCT in the treatment of a variety of autoimmune diseases versus current conventional treatments. Arranged by disease, the text provides a comprehensive guide to HSCT for all types of autoimmune/immune disorders including monogenetic autoimmune diseases; autoimmune aplastic anemia; neurologic immune diseases including multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, neuromyelitis optica, and stiff person syndrome; rheumatologic diseases such as systemic sclerosis and systemic lupus erythematosus; dermatologic diseases such as pemphigus; gastrointestinal disorders such as Crohn’s disease and celiac disease; and immune-mediated endocrinologic disease type I diabetes mellitus. Guidance is provided on the transplantation technique, cell collection and processing, conditioning regimens, infections, and early and late complications. Key Features Outlines therapies and techniques for HSCT for autoimmune diseases Discusses the advantages of HSCT over conventional therapies Reviews the entire process of stem cell therapy from harvest and ethics to indications, efficacy, and regulatory oversight |
| allogeneic car t therapy: Guidelines for Preparing Patent Landscape Reports World Intellectual Property Organization, 2015-08-24 These Guidelines are designed both for general users of patent information, as well as for those involved in producing Patent Landscape Reports (PLRs). They provide step-by-step instructions on how to prepare a PLR, as well as background information such as objectives, patent analytics, concepts and frameworks. |
| allogeneic car t therapy: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice MiKaela M. Olsen, Kristine B. LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, 2022 Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice-- |
| allogeneic car t therapy: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| allogeneic car t therapy: Brain Tumor Imaging Elke Hattingen, Ulrich Pilatus, 2015-09-02 This book describes the basics, the challenges and the limitations of state of the art brain tumor imaging and examines in detail its impact on diagnosis and treatment monitoring. It opens with an introduction to the clinically relevant physical principles of brain imaging. Since MR methodology plays a crucial role in brain imaging, the fundamental aspects of MR spectroscopy, MR perfusion and diffusion-weighted MR methods are described, focusing on the specific demands of brain tumor imaging. The potential and the limits of new imaging methodology are carefully addressed and compared to conventional MR imaging. In the main part of the book, the most important imaging criteria for the differential diagnosis of solid and necrotic brain tumors are delineated and illustrated in examples. A closing section is devoted to the use of MR methods for the monitoring of brain tumor therapy. The book is intended for radiologists, neurologists, neurosurgeons, oncologists and other scientists in the biomedical field with an interest in neuro-oncology. |
| allogeneic car t therapy: Cancer Cell Lines Part 1 John Masters, Bernhard Ø Palsson, 2006-04-11 Continuous cell lines derived from human cancers are the most widely used resource in laboratory-based cancer research. The first 3 volumes of this series on Human Cell Culture are devoted to these cancer cell lines. The chapters in these first 3 volumes have a common aim. Their purpose is to address 3 questions of fundamental importance to the relevance of human cancer cell lines as model systems of each type of cancer: 1. Do the cell lines available accurately represent the clinical presentation? 2. Do the cell lines accurately represent the histopathology of the original tumors? 3. Do the cell lines accurately represent the molecular genetics of this type of cancer? The cancer cell lines available are derived, in most cases, from the more aggressive and advanced cancers. There are few cell lines derived from low grade organ-confined cancers. This gap can be filled with conditionally immortalized human cancer cell lines. We do not know why the success rate for establishing cell lines is so low for some types of cancer and so high for others. The histopathology of the tumor of origin and the extent to which the derived cell line retains the differentiated features of that tumor are critical. The concept that a single cell line derived from a tumor at a particular site is representative of tumors at that site is naïve and misleading. |
| allogeneic car t therapy: Immunopharmacogenomics Yusuke Nakamura, 2015-09-18 This book proposes immunogenomics, or immunopharmacogenomics, as the next-generation big science to uncover the role that the immune system plays in the pathogenesis of many diseases, by summarizing the importance of the deep sequencing of T-cell and B-cell receptors. Immunogenomics/immunopharmacogenomics, a genetic characterization of the immune system made possible by next-generation sequencing (NGS), will be important for the further understanding of the pathogenesis of various disease conditions. Abnormal immune responses in the body lead to development of autoimmune diseases and food allergies. Rejection of recipient cells and tissues, as well as severe immune reactions to donor cells, is also the result of uncontrolled immune responses in the recipient body. There have been many reports indicating that activated immune responses caused by the interaction of drugs and HLA are present in drug-induced skin hypersensitivity and liver toxicity. The importance of the host immune responses has been recognized in cancer treatments, not only for immunotherapy but also for cytotoxic agents and molecular targeted drugs. Hence, characterization of the T-cell receptor and B-cell receptor repertoire by means of NGS deep sequencing will ultimately make possible the identification of the molecular mechanisms that underlie various diseases and drug responses. In addition, this approach may contribute to the identification of antigens associated with the onset or progression of autoimmune diseases as well as food allergies. Although the germline alterations and somatic mutations have been extensively analyzed, changes or alterations of the immune responses during the course of various disease conditions or during various treatments have not been analyzed. It is also clear that computational analyses to draw meaningful inferences of functional recognition receptors on the immune cells remain a huge challenge. |
| allogeneic car t therapy: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| allogeneic car t therapy: Bioreactor Systems for Tissue Engineering Cornelia Kasper, Martijn van Griensven, Ralf Pörtner, 2009-02-03 The editors of this special volume would first like to thank all authors for their excellent contributions. We would also like to thank Prof. Dr. Thomas Scheper, Dr. Marion Hertel and Ulrike Kreusel for providing the opportunity to compose this volume and Springer for organizational and technical support. Tissue engineering represents one of the major emerging fields in modern b- technology; it combines different subjects ranging from biological and material sciences to engineering and clinical disciplines. The aim of tissue engineering is the development of therapeutic approaches to substitute diseased organs or tissues or improve their function. Therefore, three dimensional biocompatible materials are seeded with cells and cultivated in suitable systems to generate functional tissues. Many different aspects play a role in the formation of 3D tissue structures. In the first place the source of the used cells is of the utmost importance. To prevent tissue rejection or immune response, preferentially autologous cells are now used. In particular, stem cells from different sources are gaining exceptional importance as they can be differentiated into different tissues by using special media and supplements. In the field of biomaterials, numerous scaffold materials already exist but new composites are also being developed based on polymeric, natural or xenogenic sources. Moreover, a very important issue in tissue en- neering is the formation of tissues under well defined, controlled and reprod- ible conditions. Therefore, a substantial number of new bioreactors have been developed. |
| allogeneic car t therapy: Adoptive Immunotherapy Burkhard Ludewig, Matthias W. Hoffmann, 2008-02-02 An authoritative collection of optimal techniques for producing and characterizing the immunologically active cells and effector molecules now gaining wide use in the clinical treatment of patients. Taking advantage of the latest technologies, the authors present readily reproducible experimental protocols for the study of dendritic cells, T cells, monoclonal antibodies, and bone marrow transplantation. The emphasis is on preclinicical and clinical applications and on the progress of selected approaches in clinical trials. Additional chapters cover the molecular definition of target antigens, mathematical modeling approaches to immunotherapy, and the utilization of regulatory T cells. The protocols make it possible to study the adoptive transfer of tailored antigen-specific immune cells and to improve the clinical application of adoptive immunotherapy. |
| allogeneic car t therapy: Natural Killer Cells Srinivas S. Somanchi, 2016-05-13 This volume contains collection of Natural Killer Cell methodologies relevant for both basic and translational research. These methodologies present new developments in the natural killer (NK) cell field, such as understanding the influence of NK cells metabolism on its function, identifying complexity of NK cell subsets through mass cytometry, and determining the emergence of memory NK cells in murine model of MCMV infection. Methods that study NK cell migration and cytotoxicity through endpoint analysis or live single cell imaging are also discussed. Chapters also describe methods pertaining to translational application of NK cells, such as ex vivo expansion of NK cells on K562 cell lines genetically modified to express either membrane bound IL-15 or membrane bound IL-21, large scale NK cell culture, current techniques for engineering NK cells to express chimeric antigen receptors or chemokine receptors using retroviral vectors, electroporation of mRNA, and the natural phenomenon of trogocytosis. Written in the highly successful Methods in Molecular Biology series format, these chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting edge and thorough, Natural Killer Cells: Methods and Protocols is a valuable resource for researchers who not only want to understand mechanisms that govern NK cell behavior and diversity, but also for those who want to understand how to systematically evaluate NK cells for adoptive immunotherapy applications. |
| allogeneic car t therapy: Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation Gerard Socie, Robert Zeiser, Bruce R. Blazar, 2018-11-22 Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation: Models in Discovery and Translation, Second Edition once again provides clinical and scientific researchers with a deep understanding of the current research in this field and the implications for translational practice. By providing an overview of the immune biology of HSCT, an explanation of immune rejection, and detail on antigens and their role in HSCT success, this book embraces biologists and clinicians who need a broad view of the deeply complex processes involved. It then moves on to discuss the immunobiology mechanisms that influence graft-versus-host disease (GVHD), graft-versus-leukemia effect, and transplantation success. Using illustrative figures, highlighting key issues, describing recent successes, and discussing unanswered questions, this book sums up the current state of HSCT to enhance the prospects for the future. The second edition is fully revised and includes new chapters on microbiome, metabolism, kinase targets, micro-RNA and mRNA regulatory mechanisms, signaling pathways in GVHD, innate lymphoid system development, recovery and function in GVHD, genetically engineered T-cell therapies, immune system engagers for GVHD and graft-versus-tumor, and hematopoietic cell transplant for tolerance induction in solid organ grafts. - Brings together perspectives from leading laboratories and clinical research groups to highlight advances from bench to the bedside - Guides readers through the caveats that must be considered when drawing conclusions from studies with animal models before correlating to clinical allogeneic hematopoietic stem cell transplantation (HSCT) scenarios - Categorizes the published advances in various aspects of immune biology of allogeneic HSCT to illustrate opportunities for clinical applications |
| allogeneic car t therapy: Epidemiology of Endocrine Tumors Jahangir Moini, Craig Badolato, Raheleh Ahangari, 2021-03-03 Epidemiology of Endocrine Tumors brings current data and clinical research into one source for a multidisciplinary audience. The book discusses the prevalence, incidence, etiology, pathology, diagnosis and treatment of various endocrine tumors. With clear and focused writing, it is essential reading for healthcare professionals, endocrinologists, oncologists, and public health professionals. Users will be able to bridge the knowledge gap that exists in the comprehensive coverage surrounding the epidemiology of endocrine tumors. Globally, the prevalence and incidence of endocrine tumors is high. This audience needs a treatise where they can gain a broad overview of endocrine tumors with a focus on epidemiology. - Supplies information about the epidemiology of various endocrine tumors, both benign and malignant, to endocrinologists, oncologists and related health care professionals - Focuses on the impact upon costs and patient deaths due to complications of these tumors - Describes how endocrine tumors affect various age groups and ethnicities, discussing the prevention of endocrine tumors - Presents chapters on Cancer Problem, Specific Endocrine Tumors, Prevention, Detection and Diagnosis, and Treatment of Endocrine Tumors - Provides review questions with an answer key and detailed glossary |
| allogeneic car t therapy: Advances in childhood leukemia , 1982 |
| allogeneic car t therapy: Developing a Protocol for Observational Comparative Effectiveness Research: A User's Guide Agency for Health Care Research and Quality (U.S.), 2013-02-21 This User’s Guide is a resource for investigators and stakeholders who develop and review observational comparative effectiveness research protocols. It explains how to (1) identify key considerations and best practices for research design; (2) build a protocol based on these standards and best practices; and (3) judge the adequacy and completeness of a protocol. Eleven chapters cover all aspects of research design, including: developing study objectives, defining and refining study questions, addressing the heterogeneity of treatment effect, characterizing exposure, selecting a comparator, defining and measuring outcomes, and identifying optimal data sources. Checklists of guidance and key considerations for protocols are provided at the end of each chapter. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews. More more information, please consult the Agency website: www.effectivehealthcare.ahrq.gov) |
| allogeneic car t therapy: Encyclopedia of Biomedical Gerontology , 2019-11-20 Encyclopedia of Biomedical Gerontology, Three Volume Set presents a wide range of topics, ranging from what happens in the body during aging, the reasons and mechanisms relating to those age-related changes, and their clinical, psychological and social modulators and determinants. The book covers the biological and medical aspects of gerontology within the general framework of the biological basis of assessing age, biological mechanisms of aging, age-related changes in biological systems, human age-related diseases, the biomedical practicality and impracticality of interventions, and finally, the ethics of intervention. Provides a ‘one-stop’ resource to information written by world-leading scholars in the field of biomedical gerontology Fills a critical gap of information in a field that has seen significant progress in the last 10 years |
| allogeneic car t therapy: Allogeneic Stem Cell Transplantation Hillard M. Lazarus, Mary J. Laughlin, 2010-03-02 Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation. |
| allogeneic car t therapy: Treatment of Leukemia and Lymphoma David A. Scheinberg, Joseph G. Jurcic, 2004-10-30 New Treatments of Leukemia and Lymphoma describes the most important advances in the therapy of hematopoietic cancers that have been derived from recent discoveries in cancer cell biology, kinase biochemistry, and immunology. Detailed descriptions of the large number of new and effective agents that have recently become available for the treatment of leukemias and lymphomas as well as an understanding of their mechanisms of action and their integration into current therapy are provided. A number of experimental drug reagents currently in clinical investigation are also discussed. The therapies include conventional anti-metabolites, monoclonal antibodies directed to cell surface receptors, antibodies tagged with toxins and radiopharmaceuticals, inhibitors of specific kinases, stem cell transplants, and engineered T-cells designed to selectively target hematopoietic cancers. The contents of the book will allow practitioners and investigators alike to understand what is current and state of the art as well as what to look for in the future.* Provides an up-to-date, state of the art discussion of a rapidly changing field * Great breadth covering conventional chemotherapeutic agents, biologic agents such as antibodies, novel small molecule inhibitors and genetically engineered cells * Written by international experts in each of the fields |
| allogeneic car t therapy: New Targeting in The Reversal of Resistant Glioblastomas Ali Syed Arbab, 2021-03-10 New Targeting in The Reversal of Resistant Glioblastomas discusses alternative treatment strategies that not only target tumor cells but also target the tumor microenvironment, metabolic pathways and interaction of cytokines in tumor cells. The current treatment for primary and recurrent glioblastomas is failing because clinicians are not considering the effect of bone marrow derived cells to the development of resistance to clinically practiced therapies. This book helps readers rethink treatment strategies to successfully fight glioblastomas. It is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field. Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma |
| allogeneic car t therapy: Immunotherapy of Hepatocellular Carcinoma Tim F. Greten, 2018-08-22 In this book we provide insights into liver – cancer and immunology. Experts in the field provide an overview over fundamental immunological questions in liver cancer and tumorimmunology, which form the base for immune based approaches in HCC, which gain increasing interest in the community due to first promising results obtained in early clinical trials. Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death in the United States. Treatment options are limited. Viral hepatitis is one of the major risk factors for HCC, which represents a typical “inflammation-induced” cancer. Immune-based treatment approaches have revolutionized oncology in recent years. Various treatment strategies have received FDA approval including dendritic cell vaccination, for prostate cancer as well as immune checkpoint inhibition targeting the CTLA4 or the PD1/PDL1 axis in melanoma, lung, and kidney cancer. Additionally, cell based therapies (adoptive T cell therapy, CAR T cells and TCR transduced T cells) have demonstrated significant efficacy in patients with B cell malignancies and melanoma. Immune checkpoint inhibitors in particular have generated enormous excitement across the entire field of oncology, providing a significant benefit to a minority of patients. |
| allogeneic car t therapy: Verbal Perseveration Jacqueline Ann Stark, 2007 Introductory textbooks on neurogenic communication disorders associated with aphasia and brain injury do not provide full documentation of the pervasive influence of perseveration in the diagnosis and treatment of clients with severe language processing deficits. This special issue of Aphasiology aims to revives the profound interest in verbal perseveration observed in the classical German literature between 1890 and 1931. Various aspects of the phenomenon of perseveration are addressed in this issue. When and under what circumstances do perseverations occur? What are the characteristics of perseverative errors and how do they relate to non-perseverative sound and word errors? The papers share a common goal, namely to understand the origin of the phenomenon 'perseveration' in healthy subjects and clients with brain damage and injury. An overarching claim throughout the papers is that perseveration reflects the client's primary language processing deficits. |
| allogeneic car t therapy: Immunotherapies for Acute Myeloid Leukemia Jochen Greiner, 2020 The efficacy of immunotherapeutic approaches in the treatment of different cancer types is becoming increasingly obvious, and immunotherapies in cancer treatment have experienced a significant breakthrough in the last few years. Immunotherapy encompasses several diverse treatment approaches, each of which has a distinct mechanism of action, and all of which are designed to boost or restore immune function in some manner. Consequently, T cell activating immunotherapeutic approaches like immune checkpoint inhibition, chimeric antigen receptor T cells (CARs), or bi-specific T cell activating antibodies are becoming increasingly important treatment strategies in different solid tumor types as well as in hematological malignancies. T cell responses against malignant cells play a major role in maintaining remission and prolonging overall survival in patients after allogeneic stem cell transplantation and donor lymphocyte infusions (DLI) due to the graft-versus-leukemia effect. In acute myeloid leukemia (AML) after intensive chemotherapy, most patients achieve complete remission; however, the overall survival for all AML patients, especially in elderly patients, is still relatively low. Immunotherapeutic approaches for AML patients might be options to reduce the relapse rate and improve overall survival. This Special Issue will focus on immunotherapeutic approaches in AML in established therapies, like the allogeneic stem cell transplantation including new concepts improving the graft-versus-leukemia effect, but also on new efforts to improve immune responses like adoptive T cell transfer, immune checkpoint inhibition, bi-specific antibodies, and CAR-T-cell approaches. |
| allogeneic car t therapy: Engineered Targeted Cancer Immunotherapies Massimo Fantini, Roberto Bei, 2022-08-01 |
| allogeneic car t therapy: Fast Facts: CAR T-Cell Therapy Richard J. Buka, Ankit J. Kansagra, 2021-02-28 Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. The results from their use in cancer immunotherapy have been very promising, but treatment is often associated with frequent, serious short-term toxicities. 'Fast Facts: CAR-T Therapy' explains what CAR T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field. Table of Contents: • CAR T cells • Clinical application • Practical aspects • Future directions |
Creating the Shift from Autologous to Allogeneic CAR T Therapy
Deep understanding of CAR T manufacturing needs and notable success piloting a CAR T to approval
Allogeneic CAR T Cells Derived From Younger Donor T Cells …
Allogene therapies utilize TALEN® gene-editing technology pioneered and owned by Cellectis. ALLO-501 and ALLO-501A are anti-CD19 AlloCAR TTM therapies being jointly developed …
Considerations for the Development of Chimeric Antigen …
In this guidance, we, FDA, provide CAR T cell-specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and design of clinical studies …
Allogeneic CD19-targeted CAR-T therapy in patients with …
Here, we genetically engineered healthy-donor-derived, CD19-targeting CAR-T cells using CRISPR-Cas9 to address the issue of immune rejec-tion and treated one patient with …
Allogeneic CAR T cells for autoimmune diseases: a glimpse …
use of allogeneic anti-CD19 CAR T cells in patients with therapy-resistant autoimmune diseases, demonstrating their effectiveness in reducing disease activity, with good tolerability and...
ADI-270: an armored allogeneic “off-the-shelf” CAR γδ T cell …
Here we report the manufacturability and functionality of ADI-270, an allogeneic γδ T cell product expressing a CD27 natural receptor third-generation CAR armored with a dominant negative …
P-BCMA-ALLO1 a non-viral allogeneic anti-BCMA CAR T …
•Allogeneic CAR-T equivalent or better than unedited healthy donor CAR-T in vitro & in vivo •Robust non-viral manufacturing process compatible with majority of healthy donors & ability to …
Minimally modified off-the-shelf allogeneic CAR T cells - Cell …
Using therapeutic allogeneic abT cells creates two challenges: (1) the native T cell receptor (TCR) can cause graft versus host disease (GVHD), and conversely, (2) alloreactive host T cells and …
Allogeneic approach unlocks CAR T cell benefits in solid …
Integrating CAR T cell treatment with transcriptional analyses reveals differences in post-infusion gene signatures, which suggests enhanced functionality of allogeneic CAR T cells in...
Chimeric antigen receptor–T cell therapy manufacturing: …
In this article, we examine production costs of an allogeneic CAR-T cell process and the poten-tial differential manufacturing costs between regions. Two offshore locations are compared with …
Preclinical Evaluation of ALLO‑329: Allogeneic CD19 CAR T …
A CD19/CD70 dual CAR T cell therapy may therefore reduce or eliminate the need for lymphodepleting conditioning regimens that are typically required prior to CAR T cell infusion.
CYAD-101: An innovative non-gene edited allogeneic CAR-T …
CYAD-101 is a novel, first-in-class, allogeneic NKG2D receptor-based CAR T-cell therapy (Figure 1). The allogeneic CYAD-101 CAR T-cell product uses a non-gene edited T-cell receptor …
Allogeneic CD19-targeted CAR-T therapy in refractory …
In this study, we have developed a healthy-donor-derived, multiplex genome-edited allogeneic CD19-targeted CAR-T product for the treatment of 3 patients with refractory and se-vere SLE.
ADI-001: An allogeneic CD20-targeted γδ CAR T cell therapy …
ADI-001: A First Allogeneic CAR γδ T Cell Therapy 3 ADI-001 is a first-in-class, allogeneic CAR γδ T cell therapy targeting the B-cell antigen CD20 with a novel human binder ADI-001 …
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT …
Our findings suggest that sequential CD7 CAR T-cell therapy and haploidentical HSCT is safe and effective, with remission and serious but reversible adverse events. This strategy offers...
Genetically modified CD7-targeting allogeneic CAR-T cell …
Allogeneic CAR-T cells, generated from healthy donor T cells, can provide ready-to-use, blast-free therapeutic products, but their application could be complicated by graft-versus-host...
NKG2D and Novel Approaches to Allogeneic CAR T - Celyad
chimeric antigen receptor T cell (CAR T) therapies •Leader in NKG2D receptor CAR T cell therapy landscape •NKG2D receptor CAR T candidates target eight different stress ligands expressed …
I2U - CAR-T Therapy- A Next Gen Immunotherapy
One budding research direction for CAR-T Therapy is the development of allogeneic CAR-T Therapies, that use donor cells and essentially removes the need to extract T-cells from patients.
The next-generation CAR-T therapy landscape - Nature
Caribou’s CB-010, an alloge-neic anti-CD19 CAR-T therapy, reduces GvHD risks by knocking out the T cell receptor α constant gene.
Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy
CAR T-cell therapy involves isolating a patient’s T cells and then transfecting them with the CAR gene, expanding the cells, and re-infusing them into the patient. Tisagenlecleucel (Kymriah®) …
Creating the Shift from Autologous to Allogeneic CAR T …
Deep understanding of CAR T manufacturing needs and notable success piloting a CAR T to approval
Allogeneic CAR T Cells Derived From Younger Donor T Cells …
Allogene therapies utilize TALEN® gene-editing technology pioneered and owned by Cellectis. ALLO-501 and ALLO-501A are anti-CD19 AlloCAR TTM therapies being jointly developed …
Considerations for the Development of Chimeric Antigen …
In this guidance, we, FDA, provide CAR T cell-specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and design of clinical studies …
Allogeneic CD19-targeted CAR-T therapy in patients with …
Here, we genetically engineered healthy-donor-derived, CD19-targeting CAR-T cells using CRISPR-Cas9 to address the issue of immune rejec-tion and treated one patient with …
Allogeneic CAR T cells for autoimmune diseases: a glimpse …
use of allogeneic anti-CD19 CAR T cells in patients with therapy-resistant autoimmune diseases, demonstrating their effectiveness in reducing disease activity, with good tolerability and...
ADI-270: an armored allogeneic “off-the-shelf” CAR γδ T cell …
Here we report the manufacturability and functionality of ADI-270, an allogeneic γδ T cell product expressing a CD27 natural receptor third-generation CAR armored with a dominant negative …
P-BCMA-ALLO1 a non-viral allogeneic anti-BCMA CAR T …
•Allogeneic CAR-T equivalent or better than unedited healthy donor CAR-T in vitro & in vivo •Robust non-viral manufacturing process compatible with majority of healthy donors & ability to …
Minimally modified off-the-shelf allogeneic CAR T cells - Cell …
Using therapeutic allogeneic abT cells creates two challenges: (1) the native T cell receptor (TCR) can cause graft versus host disease (GVHD), and conversely, (2) alloreactive host T cells and …
Allogeneic approach unlocks CAR T cell benefits in solid …
Integrating CAR T cell treatment with transcriptional analyses reveals differences in post-infusion gene signatures, which suggests enhanced functionality of allogeneic CAR T cells in...
Chimeric antigen receptor–T cell therapy manufacturing: …
In this article, we examine production costs of an allogeneic CAR-T cell process and the poten-tial differential manufacturing costs between regions. Two offshore locations are compared with …
Preclinical Evaluation of ALLO‑329: Allogeneic CD19 CAR T …
A CD19/CD70 dual CAR T cell therapy may therefore reduce or eliminate the need for lymphodepleting conditioning regimens that are typically required prior to CAR T cell infusion.
CYAD-101: An innovative non-gene edited allogeneic CAR-T …
CYAD-101 is a novel, first-in-class, allogeneic NKG2D receptor-based CAR T-cell therapy (Figure 1). The allogeneic CYAD-101 CAR T-cell product uses a non-gene edited T-cell receptor …
Allogeneic CD19-targeted CAR-T therapy in refractory …
In this study, we have developed a healthy-donor-derived, multiplex genome-edited allogeneic CD19-targeted CAR-T product for the treatment of 3 patients with refractory and se-vere SLE.
ADI-001: An allogeneic CD20-targeted γδ CAR T cell therapy …
ADI-001: A First Allogeneic CAR γδ T Cell Therapy 3 ADI-001 is a first-in-class, allogeneic CAR γδ T cell therapy targeting the B-cell antigen CD20 with a novel human binder ADI-001 …
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT …
Our findings suggest that sequential CD7 CAR T-cell therapy and haploidentical HSCT is safe and effective, with remission and serious but reversible adverse events. This strategy offers...
Genetically modified CD7-targeting allogeneic CAR-T cell …
Allogeneic CAR-T cells, generated from healthy donor T cells, can provide ready-to-use, blast-free therapeutic products, but their application could be complicated by graft-versus-host...
NKG2D and Novel Approaches to Allogeneic CAR T - Celyad
chimeric antigen receptor T cell (CAR T) therapies •Leader in NKG2D receptor CAR T cell therapy landscape •NKG2D receptor CAR T candidates target eight different stress ligands expressed …
I2U - CAR-T Therapy- A Next Gen Immunotherapy
One budding research direction for CAR-T Therapy is the development of allogeneic CAR-T Therapies, that use donor cells and essentially removes the need to extract T-cells from patients.
The next-generation CAR-T therapy landscape - Nature
Caribou’s CB-010, an alloge-neic anti-CD19 CAR-T therapy, reduces GvHD risks by knocking out the T cell receptor α constant gene.
Facts About Chimeric Antigen Receptor (CAR) T-Cell Therapy
CAR T-cell therapy involves isolating a patient’s T cells and then transfecting them with the CAR gene, expanding the cells, and re-infusing them into the patient. Tisagenlecleucel (Kymriah®) …
